U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 40

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter received	4. Expiration Date: October 31, 2021
1. Monongalia General Hospital	August 30, 2016	
2. 1200 J.D. Anderson Drive Morgantown, WV 26505-3486	3. License number: 47-16259-01 is amended in its entirety to read as follows:	5. Docket No.: 030-10683 Reference No.:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Iodine-131 permitted by 10 CFR 35.300	C. Any	C. 1.5 curies total	C. For any iodine-131 use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.
D. Iodine-125 permitted by 10 CFR 35.400	D. Sealed Sources (Best Medical International, Inc. , Model 2301; North American Scientific, Inc., Model MED3631)	D. 600 millicuries total	D. For any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number: 47-16259-01
Amendment No. 40
Docket or Reference Number: 030-10683

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
E. Palladium-103 permitted by 10 CFR 35.400	E. Sealed Sources (Best Medical International, Inc., Model 2335; North American Scientific, Inc., Model MED3633)	E. 600 millicuries total	E. For any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 1200 J.D. Anderson Drive, Morgantown, West Virginia.

11. The Radiation Safety Officer (RSO) for this license is Mark T. Perna, M.S.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)	Material and Use
Michael A. Stewart, M.D.	35.400
C. David Burtner, M.D.	35.100, 35.200, oral administration of sodium iodide I-131
Frederick J. Gabriele, M.D.	35.100, 35.200, oral administration of sodium iodide I-131
Firas S. Almahasneh, M.D.	35.200
William L. Hirsch, Jr., M.D.	35.100, 35.200, oral administration of sodium iodide I-131
Jon S. LaPlante, M.D.	35.100, 35.200, oral administration of sodium iodide I-131

MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 47-16259-01	Docket or Reference Number 030-10683
	Amendment No. 40	

Authorized User(M.D.,D.O.,etc.)	Material and Use
John Anthony Leon, M.D.	35.100, 35.200, oral administration of sodium iodide I-131
Joseph R. Migaiolo, M.D.	35.100,35.200
David C. Rosiello, M.D.	35.100,35.200
James A. Ross, M.D.	35.100,35.200
W. Parke Thrush, M.D.	35.100, 35.200, oral administration of sodium iodide I-131
Paul A. Alappat, M.D.	35.100,35.200
Richard L. Smith, II, M.D.	35.100,35.200
Wesley D. Tuel, M.D.	35.100, 35.200, oral administration of sodium iodide I-131
Evan G. Kupec, M.D.	35.100, 35.200, oral administration of sodium iodide I-131
Garrett W. Stover, M.D.	35.100, 35.200, oral administration of sodium iodide I-131

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 47-16259-01	Docket or Reference Number 030-10683
	Amendment No. 40	

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated May 16, 2011 [ML111390327]
B. Facsimile received October 10, 2011 [ML112840139]
C. Facsimile received December 18, 2012 [ML12354A154]
D. Letter received December 28, 2012 [ML13008A498]
E. Letter received August 30, 2016 [ML16250A409]
F. Letter dated September 21, 2016 [ML16267A160]

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: September 27, 2016

By: _____
Penny Lanzisera
Region 1